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Abstract 
Extracorporeal life support (ECLS) is increasingly used in the management of patients with severe cardiopulmonary 
disease. Infections are frequently the etiologies underlying the respiratory, and occasionally cardiac, failure that neces-
sitates ECLS. Just as importantly, infections are among the most commonly reported adverse events during ECLS. 
Infections in this setting may be the sequelae of prolonged critical illness or of underlying immune dysregulation; 
they may be hospital-acquired infections, and they may or may not be attributable to the presence of ECLS itself, the 
latter being an aspect that can be difficult to determine. Current registry data and evidence from the literature offer 
some insights, but also leave open many questions regarding the nature and significance of infections reported both 
before and during ECLS, including the question of any causal link between ECLS and the development of infections. 
An ongoing lack of consistency in the identification, diagnosis, management, and prevention of infections during 
ECLS is limiting our ability to interpret literature data and thus highlighting the need for more rigorous investigation 
and standardization of definitions. This review aims to characterize the current understanding of infections associated 
with the use of ECLS, taking into account data from the updated Extracorporeal Life Support Organization Registry, 
which provides important context for understanding the epidemiology and outcomes of these patients.
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Introduction
The term extracorporeal life support (ECLS) refers to 
the use of mechanical support devices that provide gas 
exchange with or without hemodynamic support through 
an extracorporeal circuit. Blood is drained through a can-
nula situated in a central vessel (typically a vein), pumped 
through a membrane, where oxygen is delivered to the 
blood and carbon dioxide is removed, and then rein-
fused back through a cannula into a central vessel (vein 
or artery, depending on the circuit configuration and 
indication) [1]. Venovenous ECLS is the preferred con-
figuration when there is severe gas exchange impairment, 
whereas venoarterial ECLS is the appropriate configura-
tion for severe cardiac dysfunction, with or without con-
comitant respiratory failure [2, 3].
Severe forms of acute respiratory distress syndrome 
(ARDS) are the most common indication for venovenous 
ECLS, and presumed or proven infectious etiologies 
typically account for a large proportion of ARDS cases 
[4–6]. Cardiogenic shock, a condition resulting from a 
heterogeneous group of diseases, is the most common 
indication for venoarterial ECLS [1]; again, the underly-
ing etiology may be related to an infectious trigger (e.g., 
sepsis-associated cardiomyopathy, acute myocarditis, 
infective endocarditis). A clear understanding of the 
epidemiology and outcomes associated with the various 
infectious etiologies of cardiopulmonary failure is essen-
tial in order to select the patients most likely to benefit 
from ECLS. Equally important is the ability to recognize 
and manage the infectious complications that can arise 
during ECLS, which may or may not be attributable to the 
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device itself, and which may adversely impact outcomes. 
Administering ECLS involves the placement of intravas-
cular catheters, which introduces a risk of both cath-
eter site infections and catheter-associated blood stream 
infections [7]. The concomitant use of invasive mechani-
cal ventilation in many of these patients exposes them to 
the risk of developing ventilator-associated pneumonia 
(VAP) [7, 8]. The ECLS population may be particularly 
susceptible to additional nosocomial infections as a result 
of concomitant critical illness and associated prolonged 
hospitalization, which often coincides with the use of 
other indwelling catheters (e.g., non-ECLS central venous 
catheters, urinary catheters, etc.) and devices (e.g., con-
tinuous renal replacement therapies, intra-aortic balloon 
pumps, percutaneous ventricular assist devices) [9]. Fur-
thermore, underlying comorbidities, critical illness, or 
perhaps even the extracorporeal circuit itself, may cause 
immune dysregulation, potentially leading to a higher 
rate of infectious complications. The management of 
infections during ECLS is made even more challenging 
by alterations in the pharmacokinetics and pharmaco-
dynamics of antimicrobial agents in the presence of both 
critical illness and extracorporeal circuitry [10, 11]. This 
narrative review aims to characterize the current under-
standing of infections associated with ECLS, discuss the 
challenges in identifying and treating these infections, 
and highlight areas where more data are needed to better 
understand the susceptibility to and impact of infections 
in patients managed with ECLS.
Infections prior to the initiation of ECLS
Both bacterial and viral pneumonia, when leading to 
severe acute respiratory failure, are common indications 
for venovenous ECLS [4–6, 12]. With regard to specific 
infectious organisms, one of the most widely reported 
indications for ECLS in ARDS is influenza A (H1N1), 
partly as a result of the rapid increase in the use of ECLS 
during the 2009 H1N1 pandemic. Data from several 
large observational studies suggest, overall, that there is 
a probable benefit to be derived from the use of ECLS 
in H1N1-associated severe ARDS refractory to conven-
tional therapy [13–15]. Whereas no specific infectious 
etiology has been identified as a contraindication to the 
use of ECLS, co-infections in the context of influenza-
associated ARDS, including infections with S. aureus, 
multidrug-resistant Gram-negative bacteria and Asper-
gillus, may correlate with lower survival compared with 
influenza alone [16–19]. Likewise, concomitant non-
pulmonary infections at the time of initiation of ECLS 
for ARDS may predict worse outcomes and this factor 
has been incorporated into a validated prognostic scoring 
system [20].
While infectious etiologies may account for a relatively 
small proportion of the indications for venoarterial ECLS 
in cardiac failure, certain subpopulations warrant consid-
eration. Both acute myocarditis, which is often attribut-
able to infection, and sepsis-associated cardiomyopathy 
are indications that may be associated with favorable sur-
vival rates [21–23].
The Extracorporeal Life Support Organization (ELSO) 
registry is the largest international repository of epide-
miological data on ECLS. The results of an ELSO registry 
search for all infectious organisms identified on culture 
prior to the initiation of ECLS between January 1, 2012 
(correlating with a reformatting of data entry within 
the registry for more extensive detail on infections) and 
July 31, 2019 are summarized in Figs.  1 and 3a, and in 
the Online Resource, with the most common pathogens 
listed by frequency. These data should be interpreted 
with caution, as culture positivity may not represent true 
infection, and the presence of these organisms prior to 
the initiation of ECLS may or may not have contributed 
to the cardiopulmonary failure that prompted the use of 
ECLS. Furthermore, when interpreting infections iden-
tified during ECLS, it is important to take into account 
any pre-ECLS infections; indeed, without a thorough 
understanding of what was present prior to ECLS, any 
pre-existing infections may incorrectly be characterized 
as de novo ones. With regard to the frequency of posi-
tive cultures, represented as a percentage of total ECLS 
runs, it is important to remember that individual patients 
may be represented by more than one culture. Addi-
tionally, registry data is self-reported by ELSO member 
centers, and may therefore be influenced by variability in 
data collection and in interpretation of data definitions; 
furthermore, these data, even if accurate, may not be 
representative of ECLS practices at non-ELSO-affiliated 
sites. Albeit subject to these important limitations and 
caveats, the registry data search revealed 5492 positive 
cultures prior to the initiation of 17,374 distinct ECLS 
runs for respiratory failure (31.6%). Positive cultures 
prior to ECLS appeared to be much more common in the 
case of ECLS administered for respiratory failure than 
for cardiac indications (8.8% of cardiac failure runs; 7% 
of runs for extracorporeal cardiopulmonary resuscitation 
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(ECPR)), with the respiratory tract being the most fre-
quent site throughout.
Regardless of ECLS indication, S. aureus and yeast were 
consistently among the most common respiratory tract 
pathogens reported. Notably, Influenza A was the most 
commonly identified organism in the respiratory tract in 
patients receiving ECLS for respiratory failure, account-
ing for 12.7% of all organisms identified. Staphylococcus 
and Streptococcus were the most common isolates in 
the bloodstream across all indications. Yeast, E. coli, and 
Enterococcus were common pathogens in the urine.
Infections during ECLS
Reported rates of hospital-acquired infections during 
ECLS have varied substantially across case series and 
registries; these data have inherent limitations due to 
variations in definitions, reporting methods, and surveil-
lance practices. Patients receiving ECLS may be at risk 
of developing typical ICU-related nosocomial infections 
(e.g., VAP, bloodstream infections, urinary tract infec-
tions), in addition to ECLS-specific infections, such as 
localized infections at peripheral cannulation insertion 
sites or mediastinitis in the setting of central cannulation 
[7, 24]. Bizzarro et al. [25] reported a 21% prevalence rate 
of nosocomial infections among adults recorded in the 
ELSO registry from 1998–2008, whereas previous case 
series estimated nosocomial infection rates of between 9 
and 65% during ECLS [7, 26–29].
Figures  2 and 3b and the Online Resource summa-
rize the ELSO registry data documenting positive cul-
tures during ECLS administered for respiratory failure, 
cardiac failure, and cardiac arrest. ECLS for respiratory 
failure showed the highest rate of positive cultures dur-
ing ECLS (64.9%), whereas ECPR showed the lowest rate 
(22%). The distribution of pathogens during ECLS was 
found to be similar to the pre-ECLS pattern. Yeast and S. 
aureus were the most common organisms in the respira-
tory tract during ECLS across all three groups, whereas 
Staphylococcus, yeast, and Enterococcus were among the 
organisms isolated most frequently from blood cultures. 
The survival rates of individuals with positive cultures 
during ECLS administered for respiratory failure or car-
diac failure were lower than the overall survival rates of 
all ECLS recipients over a similar timeframe (54.3% vs 
61.1% and 38.0% vs 44.2%) [12], whereas survival among 
culture-positive ECPR patients was the lowest of the 
three groups but comparable to that observed in the gen-
eral ECPR population (30.2% vs 29.9%) [12]. Although 
Fig. 1 Most common organisms identified on culture prior to initiation of ECLS for respiratory and cardiac failure. Based on a total of 17,374 ECLS 
runs for respiratory failure and a total of 18,514 total ECLS runs for cardiac failure from January 2012 through July 2019. Event rate represents the 
number of positive cultures for a given organism divided by the total number of ECLS runs. ECLS extracorporeal life support
these data seem to suggest a correlation between acquisi-
tion of nosocomial infections and increased mortality, in 
the absence of further information regarding underlying 
diagnoses, comorbid conditions, and other factors that 
undoubtedly confound this association, only tentative 
conclusions can be drawn.
It is important to reiterate that these data refer only 
to organisms identified on culture and are not necessar-
ily indicative of active infections. Some of these organ-
isms may represent colonizations without pathological 
significance (e.g., the detection of Candida in the res-
piratory tract). Similarly, cultures obtained during ECLS 
may show the persistence of an organism already present 
before ECLS initiation (as in the case, for example, of a 
patient with S. aureus in the bloodstream before ECLS 
initiation who remains bacteremic during ECLS) rather 
than necessarily being indicative of  newly identified 
organisms or a new infection. That said, the ELSO reg-
istry continues to provide the most comprehensive and 
detailed body of data available on the prevalence of infec-
tions during ECLS.
Beyond registry data, the value of primary investi-
gational data from individual sites is often limited by 
methodology and generalizability issues. Having said 
that, a recent single-center observational study of 92 
patients receiving ECLS (87% venovenous ECLS), in 
whom infections were systematically and prospectively 
identified through application of well-established clini-
cal practice guidelines [30, 31], reported high rates of 
nosocomial infections (55%), with VAP and multidrug-
resistant organisms found to be common [24]. Those 
who acquired nosocomial infections had higher overall 
mortality, longer durations of mechanical ventilation and 
ECLS, and spent longer in the ICU.
Risk factors for the development of infections 
during ECLS
The etiology of nosocomial infections during ECLS has 
not been systematically compared with (although it likely 
parallels) that of infections acquired in the course of criti-
cal illness in the absence of ECLS; however it remains to 
be established whether certain characteristics unique to 
patients receiving ECLS confer an increased risk of infec-
tion. This can only be speculated upon from the existing 
data (Table 1). It has been suggested, initially in patients 
undergoing cardiopulmonary bypass, that extracorpor-
eal circuitry affects the immune system through multiple 
mechanisms (e.g., induction of endothelial dysfunction, 
Fig. 2 Most common organisms identified on culture during ECLS for respiratory and cardiac failure. Based on a total of 17,374 total ECLS runs for 
respiratory failure and a total of 18,514 total ECLS runs for cardiac failure from January 2012 through July 2019. Event rate represents the number of 
positive cultures for a given organism divided by the total number of ECLS runs. ECLS extracorporeal life support
activation of the contact system, coagulation cascade, 
neutrophils and platelets with consequent release of 
pro-inflammatory mediators) [32], and that the result-
ing immune system impairment might explain why ECLS 
may increase susceptibility to infection [33]. In contrast 
to this supposed hyperinflammatory response to ECLS, 
there exist equally compelling data suggesting that ECLS 
promotes an anti-inflammatory state through improve-
ments in end-organ perfusion and gas exchange in 
patients with severe cardiopulmonary failure and reduc-
tions in pro-inflammatory injury (e.g., ventilator-induced 
lung injury) [34, 35]. A prospective observational study 
of 262 adult patients with severe ARDS reported a rapid 
decline in IL-6 and IL-8 levels within 24  h of the start 
of venovenous ECLS. Higher cytokine levels were asso-
ciated with extra-pulmonary causes of ARDS, more 
aggressive ventilation before ECLS, and mortality [36]. 
The overall balance between pro- and anti-inflammatory 
effects (i.e., whether end-organ protective strategies out-
weigh the injurious effects of ECLS) likely determine the 
impact on the immune response and the consequent risk 
of infection. Whether these alterations pose an increased 
risk of infection after decannulation from ECLS is an area 
that warrants further investigation [37].
Whether or not the presence of ECLS leads to addi-
tional immune system impairment, immunocompro-
mised patients appear to have worse outcomes than 
immunocompetent patients. In a multicenter observa-
tional study of 203 immunocompromised patients receiv-
ing ECLS for severe ARDS, nosocomial infections were 
common, with VAP diagnosed in 50% of patients and 
cannula-associated infections (defined as local signs of 
infection at a cannula site with positive culture from sub-
cutaneous needle aspirate) found in 10% of patients [6]. 
With 6-month survival rates standing at only 30%, par-
ticular consideration should be given to preventive prac-
tices and close surveillance of infections during ECLS in 
Fig. 3 Most common organisms identified on culture prior to initiation of ECLS (a) and during ECLS (b) for cardiac arrest. Based on a total of 5979 
ECLS runs for cardiac arrest from January 2012 through July 2019. Event rate represents the number of positive cultures for a given organism divided 
by the total number of ECLS runs. ECLS extracorporeal life support
Table 1 Potential risk factors for infections during ECLS
ECLS extracorporeal life support
a There are no specific cutoffs, per se, but the longer the duration of ECLS, the 
older the age, and the higher the pre-ECLS severity of illness, the higher the 
presumed risk
Immunocompromised status (including potential immune dysregulation 
from the presence of ECLS itself )
Prolonged duration of  ECLSa
Older  agea
Higher pre-ECLS severity of  illnessa
Underlying autoimmune disorder
Central cannulation (vs peripheral cannulation)
Surgical cannulation approach (vs percutaneous approach)
this vulnerable patient population. Of note, the acquisi-
tion of nosocomial infections was not an independent 
predictor of mortality in multivariable analysis.
While ECLS duration has frequently been associated 
with the development of nosocomial infections [7, 26–
29], no existing analyses are able to determine whether 
longer duration of support is a risk factor for or a con-
sequence of acquired infections. Prolonged use of ECLS 
will increase the opportunity to acquire infections, 
and infections are likely to contribute to, and increase 
the duration of, critical illness. Any relationship found 
between nosocomial infections and duration of ECLS 
should be interpreted with particular caution, as patients 
who acquire and die from infections early in their hos-
pitalization would obviously have had shorter ECLS 
durations.
Older age, higher pre-ECLS severity of illness, under-
lying autoimmune disorders, circuit configurations, and 
performance of procedures during ECLS have all been 
implicated as risk factors for infections during ECLS [24, 
27–29, 38, 39]. However, given the predominantly single-
center, retrospective nature of the cited studies, the pos-
sibility of determining the true incremental risk, if any, 
deriving from these factors is limited and warrants more 
systematic investigation. Of note, Grasselli et  al. identi-
fied younger, not older, age as being independently asso-
ciated with higher risk of nosocomial infections, with 
VAP and multidrug-resistant organisms associated with 
higher mortality [24].
Whether the site and number of ECLS cannulae is asso-
ciated with increased infection risk has yet to be thor-
oughly investigated. There is weak evidence suggesting an 
increased risk of infection with central cannulation and a 
decreased risk with single-site, dual-lumen cannulae [7, 
38]. In a recent single-center propensity score-matched 
analysis of 814 patients undergoing venoarterial ECLS, 
cannula site infections were significantly more common 
with a surgical approach than a percutaneous approach 
(27.8% vs 16.5%, p < 0.001) [40]. Historical data suggest an 
increased incidence of bloodstream infections in ECLS 
patients compared with non-ECLS critically ill patients 
[41], although this has not been corroborated in the era 
of modern ECLS technology and practices. Cannulae 
and membranes are both potential surfaces for microbial 
colonization, as demonstrated by several studies [42–44]. 
Whether these surfaces represent primary or secondary 
sites of infection is not currently known.
Challenges in the detection, treatment, 
and prevention of infections during ECLS
Efforts to detect infections during ECLS come up against 
particular difficulties that could impede their prompt 
recognition and treatment, as well as the assessment of 
response to antimicrobial therapy. Passive or active cool-
ing or heating of the blood as it passes through the mem-
brane may mask fever or hypothermia [11]. The presence 
of infiltrates on chest radiographs, used to help identify 
VAP [31], may be difficult to interpret when extreme 
lung-protective ventilatory strategies are employed, as 
these result in extensive airspace opacification in the 
absence of a new infection [13], or in cases of severe 
cardiogenic pulmonary edema. The potential for ECLS 
to affect serological tests used in the detection of infec-
tions, much in the way cellulose membranes may elevate 
1,3-β-d-glucan levels [45], is an important considera-
tion that warrants further investigation. The difficulty in 
detecting infection by conventional means may influence 
surveillance practices, as highlighted by a high reported 
rate of daily blood cultures performed as routine surveil-
lance in a survey of ELSO-affiliated ECLS centers [46].
The pharmacokinetics and pharmacodynamics of anti-
microbial agents used to treat infections during ECLS 
may be affected by several factors associated with both 
critical illness and the ECLS circuit itself, including clear-
ance abnormalities in the setting of organ failures, poten-
tial for sequestration within the circuit, and increases in 
the volume of distribution (Vd) [10, 11, 47]. The lipophi-
licity and protein binding characteristics of a given drug 
play an important role in its interaction with the circuit 
[11]. Several antibiotics have been studied in the context 
of ECLS, and shown varying susceptibility to subthera-
peutic levels due to sequestration or increased Vd; the 
results have been summarized elsewhere [10, 11]. When 
available, therapeutic drug monitoring should be per-
formed to ensure adequate dosing of medications during 
ECLS.
Despite a lack of data demonstrating benefits, and 
in spite of ELSO Infectious Disease Task Force recom-
mendations against the practice, antibiotic prophylaxis 
is commonly used at ECLS centers, according to surveys 
of ELSO member sites [46, 48, 49]. Whether or not anti-
biotic, or antifungal, prophylaxis is warranted or affects 
the incidence of nosocomial infections may become 
moot if most patients are already receiving antimicro-
bial agents at the time of initiation of ECLS. For exam-
ple, 97% of patients in the previously mentioned cohort 
of immunocompromised patients were receiving antibi-
otics before ECLS, despite in many cases not having an 
infectious etiology for their respiratory failure [6]. Other 
infection prevention practices, including cannula mainte-
nance strategies, vary across centers [46, 50]. Many of the 
recommendations put forth by ELSO, such as the use of 
sterile techniques, adherence to VAP prevention guide-
lines, and avoidance or removal of unnecessary invasive 
devices, mirror general infection prevention practices 
followed in critically ill patients (Fig.  4) [26, 49]. One 
emerging VAP prevention strategy that may be used in 
selected ECLS patients is endotracheal extubation with 
removal of invasive mechanical ventilation. Patients with 
primarily cardiac failure, who have relatively preserved 
gas exchange, patients with predominantly hypercapnic 
respiratory failure, or those in whom early mobilization 
is of greater importance to their ultimate recovery, such 
as patients receiving ECLS as a bridge to transplantation, 
may be particularly suitable for such a strategy [51]. The 
roles of other infection prevention strategies that have 
been explored in general critical care populations, such 
as selective digestive decontamination, remain uncertain 
in ECLS patients.
Future research directions
The paucity of high-quality data on ECLS-associated 
infections highlights the need for a more systematic 
evaluation of their incidence, outcomes and risk fac-
tors, and of appropriate prevention approaches and 
treatment strategies (Fig. 5). Without consistent defini-
tions of ECLS-associated infections (including infec-
tions attributed to the device itself ) and standardized 
reporting of these events, it remains impossible to 
quantify the true incidence of infections both before 
and after the initiation of ECLS, including infections 
acquired after ECLS removal. A better understanding 
of infection susceptibility during ECLS would help to 
clarify whether antimicrobial prophylaxis or routine 
surveillance cultures might be warranted in certain 
patient populations, or perhaps whether ECLS should 
be avoided altogether in the presence of infections with 
universally poor outcomes.
A systematic review has previously characterized 
inconsistencies existing in the definition and report-
ing of infectious complications in venoarterial ECLS 
[52], highlighting the need for methodologically rigor-
ous development of consensus opinions regarding infec-
tious complications and associated outcomes in order to 
obtain accurate and clinically meaningful epidemiologi-
cal data [53]. The ELSO registry is currently undergoing 
a redesign that may allow for more granularity regarding 
infectious indications and complications [54].
Ideally, in order to be generalizable to the broader 
ECLS community, studies evaluating the epidemiol-
ogy of ECLS-associated infections should be performed 
across diverse patient populations with varying rates of 
organism prevalence and antimicrobial resistance, using 
standardized definitions of infections, and systematically 
measuring important confounders that may contribute to 
infections and outcomes. Along such lines, a multicenter, 
prospective observational study evaluating the preva-
lence of nosocomial infections and cannula management 
practices in ECLS across Australia and New Zealand has 
recently been proposed [55]. Research networks, such 
as the International ECMO Network (ECMONet; www.
inter natio nalec monet work.org), provide a forum for per-
forming this type of research in ECLS across centers and 
regions. In the meantime, we recommend that all centers 
Fig. 4 Potential strategies to reduce infections during ECLS. ECLS extracorporeal life support, VAP ventilator-associated pneumonia
performing ECLS enter their data into the ELSO or other 
equivalent registry.
In addition to epidemiological data, more information 
is needed regarding antimicrobial pharmacokinetics and 
pharmacodynamics during ECLS in order to optimize 
treatment of peri-ECLS infections. The ongoing Anal-
gesia, Sedation, and Antibiotic Pharmacokinetics during 
Extracorporeal Membrane Oxygenation (ASAP ECMO) 
study hopes to provide additional insight into the impact 
of ECLS on the efficacy of antimicrobials [56].
Conclusions
Infections both commonly precede and are frequently 
identified during ECLS. This review of current knowl-
edge regarding ECLS-associated infections highlights 
the need for standardized definitions, consistent detec-
tion strategies, and more comprehensive descriptions of 
patient characteristics and outcomes so that meaningful 
conclusions regarding the clinical significance of these 
infections can be drawn and inform best practices for 
their prevention and management.
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